Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GCK | P35557 | 7/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | METAP1 | P53582 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906740 | 0.91 | CBFB (0.59) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14892344 | 0.88 | CBFB (0.55) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL20350768 | 0.86 | CBFB (0.59) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14892719 | 0.83 | CBFB (0.56) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL125111 | 0.81 | CBFB (0.67) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14892725 | 0.81 | ALDH1A1 (0.39) | NPC1RAB9ASMN1; SMN2PKMKDM4E | |
| SCHEMBL14892359 | 0.81 | CBFB (0.53) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14892238 | 0.81 | CBFB (0.53) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL125289 | 0.80 | CBFB (0.65) | CBFBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14892245 | 0.80 | CBFB (0.57) | CBFBNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | CBFB 688/4885NPC1 230/4885RAB9A 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.